Fortrea Holdings Inc (FTRE)
$24.85
Insights on Fortrea Holdings Inc
Decreasing Revenue
Revenue is down for the last 4 quarters, 793.0M → 662.1M (in $), with an average decrease of 5.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, 28.3M → -101.0M (in $), with an average decrease of 167.2% per quarter
Performance
- $24.60$25.66$24.85
1.01%
Downside
Day's Volatility :4.13%
Upside
3.16%
- $24.18$41.02$24.85
2.7%
Downside
52 Weeks Volatility :41.05%
Upside
39.42%
Returns
| Period | Fortrea Holdings Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -32.29% | 0.0% |
6 Months | -21.46% | 0.0% |
1 Year | -32.55% | 0.0% |
3 Years | -32.55% | -22.6% |
Highlights
Market Capitalization | 2.2B |
Book Value | $17.81 |
Earnings Per Share (EPS) | -1.02 |
Wall Street Target Price | 31.81 |
Profit Margin | -3.8% |
Operating Margin TTM | -5.15% |
Return On Assets TTM | 0.56% |
Return On Equity TTM | -3.65% |
Revenue TTM | 3.1B |
Revenue Per Share TTM | 34.61 |
Quarterly Revenue Growth YOY | -4.6% |
Gross Profit TTM | 0.0 |
EBITDA | 136.0M |
Diluted Eps TTM | -1.02 |
Quarterly Earnings Growth YOY | -0.57 |
EPS Estimate Current Year | 0.72 |
EPS Estimate Next Year | 1.68 |
EPS Estimate Current Quarter | 0.01 |
EPS Estimate Next Quarter | 0.15 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 28.01%
Technicals Summary
Sell
Neutral
Buy
Fortrea Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Fortrea Holdings Inc | -31.62% | -21.46% | -32.55% | -32.55% | -32.55% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.18% | 31.88% | 93.3% | 227.58% |
 Novo Nordisk A/s | 8.85% | 34.38% | 71.83% | 235.07% | 463.44% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 34.1% | 40.6% | 123.97% | 174.53% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Fortrea Holdings Inc | 467.67 | NA | NA | 0.72 | -0.04 | 0.01 | NA | 17.81 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Fortrea Holdings Inc | Buy | $2.2B | -32.55% | 467.67 | -3.8% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 227.58% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 463.44% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 174.53% | 29.59 | 39.46% |
Company Information
Organization | Fortrea Holdings Inc |
Employees | 16000 |
CEO | Mr. Thomas H. Pike |
Industry | Miscellaneous |
Discover More
Chewy, Inc.
$24.85
-2.13%
Mr. Cooper Group Inc.
$24.85
-2.13%
Janus Henderson Mortgage-backed Securities Etf
$24.85
-2.13%
Dnp Select Income Closed Fund
$24.85
-2.13%
Dimensional Us Core Equity M
$24.85
-2.13%
Principal Us Mega-cap Etf
$24.85
-2.13%
Goldman Sachs Marketbeta Us
$24.85
-2.13%
Spdr Portfolio Long Term Treasury Etf
$24.85
-2.13%
Crinetics Pharmaceuticals Inc
$24.85
-2.13%